Фибрилляция предсердий

28. Fuster V. et al. ACC/AHA/ESC guidelines for the management of patients with atrial brillation // J. Am. Coll. Cardiol. 2001. Vol. 38. P. 1231–1266.

29. Nieuwlaat R. et al. The Euro Heart Survey on Atrial Fibrillation // Am. Heart J. 2007. Vol. 153. P. 1006–1012.

30. Сулимов В.А. Российское кардиологическое общество, Национальные рекомендации по диагностике и лечению фибрилляции предсердий, 2012

31. Bodin L., Horellou M.H., Flaujac C. et al. A vitamin K epoxide reductase complex subunit–1 (VKORC1) mutation in a patient with vitamin K antagonist resistance // J. Thromb. Haemost. –2005. – Vol. 3. – P.1533–1535.

32. Tabrizi A.R., Zehnbauer B.A., Borecki I.B. et al. The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin // J. Am. Coll. Surg. – 2002. – Vol. 194. – P. 267–273.

33. N. Engl. J. Med. 2012; 366:9–19. Copyright © 2011 Massachusetts Medical Society.

34. Christopher B. Granger, John H. Alexander, John J.V. McMurray et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation// N. Engl. J. Med

35. Connolly S.J. The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation. 2013 Jul 16; 128 (3): 237–43.

36. Go A.S., Hylek E.M., Chang Y, Phillips K.A., Henault LE, Capra A.M., Jensvold NG, Selby JV, Singer DE. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290:2685–2692.

37. Nabauer M., Gerth A., Limbourg T., Schneider S., Oeff M., Kirchhof P., Goette A., Lewalter T., Ravens U., Meinertz T., Breithardt G., Steinbeck G. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. // Europace. 2009 Apr;11(4):423–34/

38. Heeringa J., van der Kuip D.A., Hofman A., Kors J.A., van Herpen G., Stricker B.H., Stijnen T., Lip G.Y., Witteman J.C. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J 2006; 27:949–953.

39. Lin H.-J. et al. 2006, Stroke.

40. Reisinger J., Gatterer E., Lang W., Vanicek T., Eisserer G., Bachleitner T., Niemeth C., Aicher F., Grander W., Heinze G., Kuhn P., Siostrzonek P. Flecainide versus ibutilide for immediate cardioversion of atrial fibrillation of recent onset. Eur Heart J.

41. Khan I.A. Single oral loading dose of propafenone for pharmacological cardioversion of recent-onset atrial fibrillation. J. Am Coll Cardiol 2001; 37:542–547.

42. Martinez-Marcos F.J., Garcia-Garmendia J.L., Ortega-Carpio A., Fernandez-Gomez J.M., Santos J.M., Camacho C. Comparison of intravenous flecainide, propafenone, and amiodarone for conversion of acute atrial fibrillation to sinus rhythm. Am J Cardiol 2000; 86:950–953.

43. Chevalier P., Durand-Dubief A., Burri H., Cucherat M, Kirkorian G., Touboul P. Amiodarone versus placebo and class Ic drugs for cardioversion of recent-onset atrial fibrillation: a meta-analysis. J Am Coll Cardiol 2003;41: 255–262.

44. Vardas P.E., Kochiadakis G.E., Igoumenidis N.E., Tsatsakis A.M., Simantirakis E.N., Chlouverakis G.I. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 2000; 117:1538–1545.

45. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857–867.

46. Watson T., Shantsila E., Lip G.Y., 2009.

47. Vivek Y. Reddy, David Holmes et al. Safety of Percutaneous Left Atrial Appendage Closure. Circulation, 2011.

48. Hijazi Z Eur Heart 2013; 34:1475–1480.

49. Cosedis Nielsen J., Johannessen A., Raatikainen P., Hindricks G., Walfridsson H., Kongstad O. et al. A randomized comparison of radiofrequency ablation and antiarrhythmia drug therapy as first line treatment in paroxysmal atrial fibrillation. N Engl J Med 2012:in press.

50. Morillo C., Verma A., Kuck K.H. et al. Radiofrequency Ablation vs. Antiarrhythmic Drugs as First-Line Treatment of Symptomatic Atrial Fibrillation: RAAFT 2): A randomized trial. Heart Rhythm Society 2012 Scientific Sessions; May 11, 2012; Boston, MA. Abstract LB02-1.

51. Wazni O.M., Marrouche N.F., Martin D.O., Verma A., Bhargava M., Saliba W., Bash D., Schweikert R., Brachmann J., Gunther J., Gutleben K., Pisano E., Potenza D., Fanelli R., Raviele A., Themistoclakis S., Rossillo A., Bonso A., Natale A.: Radiofrequency ablation vs antiarrhythmic drugs as firstline reatment of symptomatic atrial fibrillation: A randomized trial. JAMA 2005; 293:2634–2640.

52. Boersma L.V., Castella M., van Boven W., Berruezo A., Yilmaz A., Nadal M., Sandoval E., Calvo N., Brugada J., Kelder J., Wijffels M., Mont L. Atrial fibrillation catheter ablation vs. surgical ablation treatment (FAST): a 2-center randomized clinical trial. Circulation 2012; 125:23–30.